| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On October 28, 2004
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 2001D-0584
|
| Reduce the Risk of Transmission of HIV-1 & HCV
|
|
|
|
|
| 2003N-0456
|
| Agency Information Collection:Prevention of Medical Gas Mix-ups at Health Care Facilities
|
|
|
|
|
| 2004D-0462
|
| Guidance for Industry: Criteria for Safety and Efficacy Evaluation of Oxygen Therapeutics as Red Blood Cell Substitutes
|
|
|
|
|
| 2001D-0584
|
| Reduce the Risk of Transmission of HIV-1 & HCV
|
|
|
|
|
| GDL
2
|
| Guideline
|
| Vol #:
|
| 1
|
|
|
|
|
| NAD
2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2003N-0456
|
| Agency Information Collection:Prevention of Medical Gas Mix-ups at Health Care Facilities
|
|
|
|
|
| NAL
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| SS
1
Attachment
|
| Supporting Statement
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004D-0462
|
| Guidance for Industry: Criteria for Safety and Efficacy Evaluation of Oxygen Therapeutics as Red Blood Cell Substitutes
|
|
|
|
|
| GDL
1
|
| Guideline
|
| Vol #:
|
| 1
|
|
|
|
|
| NAD
1
|
| FDA
|
| Vol #:
|
| 1
|
|
